menu search

BLUE / BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment

BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment
Sometimes, the financial markets can be highly unpredictable. Reportedly, the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold on Bluebird Bio's (NASDAQ: BLUE ) studies of a sickle cell disease (SCD) treatment candidate. Read More
Posted: Dec 19 2022, 11:50
Author Name: InvestorPlace
Views: 103075

BLUE News  

Bluebird bio to sell sickle cell gene therapy FDA voucher for $103 million if approved

By Reuters
October 30, 2023

Bluebird bio to sell sickle cell gene therapy FDA voucher for $103 million if approved

Bluebird bio said on Monday it has agreed to sell its priority review voucher for $103 million, if it gets the U.S. Food and Drug Administration's app more_horizontal

Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October

By PennyStocks
October 17, 2023

Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October

Are you looking for the best penny stocks to buy now? Today might be your day more_horizontal

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

By The Motley Fool
September 20, 2023

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and pl more_horizontal

2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

By The Motley Fool
September 12, 2023

2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebir more_horizontal

Is Bluebird Bio a Bargain Buy in September?

By The Motley Fool
August 29, 2023

Is Bluebird Bio a Bargain Buy in September?

Bluebird Bio is strapped for cash, and a lot of must-do spending is coming up. It will likely need to scale up its clinic footprint while also launchi more_horizontal

1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street

By The Motley Fool
August 24, 2023

1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street

Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another app more_horizontal

7 Very Oversold Nasdaq Stocks to Buy Right Now

By InvestorPlace
August 23, 2023

7 Very Oversold Nasdaq Stocks to Buy Right Now

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are w more_horizontal

bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee

By Zacks Investment Research
August 17, 2023

bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee

bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory com more_horizontal


Search within

Pages Search Results: